Drug Observance and Side Effects of Cytoreductive Drugs in PV and ET Patients
- Conditions
- Polycythemia VeraEssential Thrombocythemia
- Registration Number
- NCT02893410
- Lead Sponsor
- University Hospital, Brest
- Brief Summary
Patients treated with oral or sub-cutaneous drugs for polycythemia vera or essential thrombocythemia completed an unique paper questionnaire in order to describe their observance, the side effects and their own appreciation of the taken drug.
- Detailed Description
During one year, all patients with PV or ET followed in our centre, and who took a drug to treat their MPN, were identified.
The investigators submitted by mail or directly at the consultation a unique questionnaire containing 25 questions concerning patients characteristics, evaluation of observance, identification of side effects and own appreciation of the drug.
After completion of the questionnaire, the patients were identified and followed to collect new data about thrombotic events or phenotypic evolution.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 286
- Patients with PV or ET or SMF
- Patients who took oral or sub-cutaneous drugs to treat their MPN.
- Patients who agreed to complete the questionnaire
- Patients with low risk PV or ET who do not take treatment
- Patients unable to complete the questionnaire
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Rate of adherence to drug prescription At inclusion prospective evaluation in a one shot questionnaire given to each treated patient seen at the consultation distributed between december 2014 and december 2015
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
CHRU de Brest
🇫🇷Brest, France